HPV vaccination and the prevention of cervical cancer: The long road ahead

Journal of Women's Health

Volumn 16, Issue 9, 2007, Pages 1366-1367

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; COMMUNICABLE DISEASE; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; LABORATORY DIAGNOSIS; MORBIDITY; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VERRUCA VULGARIS; WOMEN'S HEALTH;

ADOLESCENT; ADULT; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION; WOMEN'S HEALTH SERVICES;

EID: 36248935547     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.ED05     Document Type: Editorial

References (11)

1. Waggoner SE. Cervical cancer. Lancet 2003; 361:2217.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA 2005;55:74.
3. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915.
4. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomized clinical trials. Lancet 2007;369:1861.
5. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 2006;367:1247.
6. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007;369:2161.
7. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6,11,16,18) L1 virus-like particle vaccine against high-grade vulvar and vaginal lesions: A combined analysis of three randomized clinical trials. Lancet 2007;369:1693.
8. Mork J, Lie A-K, Glattre, E. et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125.
9. Bjorge T, Engleland A, Luostarinen T, et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective trial. Br J Cancer 2002;87:61.
10. Vetter, KM, Geller SE. Moving forward: Human papillomavirus vaccination and the prevention of cervical cancer. J Womens Health. 2007;16:1258.
11. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813.